Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 14, Issue 4, 2007, Pages 323-328

  Fleseriu, Maria ^a   Loriaux, D Lynn ^a   Ludlam, William H ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

Author keywords

Bilateral adrenalectomy; Cushing's disease; Radiotherapy; Transsphenoidal surgery

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMINOGLUTETHIMIDE; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYPROHEPTADINE; DEXAMETHASONE; DOPAMINE RECEPTOR STIMULATING AGENT; DOXAZOSIN; ETOMIDATE; GLUCOCORTICOID; KETANSERIN; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MINERALOCORTICOID; MITOTANE; OCTREOTIDE; PASIREOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOIC ACID; RITANSERIN; ROSIGLITAZONE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; TRILOSTANE; VALPROIC ACID;

ACNE; ADRENAL INSUFFICIENCY; ADRENALECTOMY; ANOREXIA; BLEEDING TIME; BLURRED VISION; CLINICAL TRIAL; CUSHING DISEASE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; FEVER; GALLSTONE; GAMMA KNIFE RADIOSURGERY; GASTROINTESTINAL SYMPTOM; HEADACHE; HIRSUTISM; HORMONE BINDING; HORMONE DEFICIENCY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; HYPOADRENALISM; HYPOKALEMIA; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; HYPOPITUITARISM; IRRADIATION; LETHARGY; LIVER TOXICITY; NAUSEA; NELSON SYNDROME; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PROTON RADIATION; RASH; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TRANSSPHENOIDAL SURGERY; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ADRENALECTOMY; COMBINED MODALITY THERAPY; CUSHING SYNDROME; HUMANS; PITUITARY GLAND;

EID: 34447542175     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328248b498     Document Type: Review

References (53)

1. Pivonello R, Faggiano A, Lombardi G, Colao A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 2005; 34:327-339; viii.
2. Chandler W, Schteingart D. Controversies in the management of Cushing's disease. Clin Neurosurg 1986; 33:553-562.
3. Chee G, Mathias D, James R, Kendall-Taylor P. Transsphenoidal pituitary surgery in Cushing's disease: can we predict outcome? Clin Endocrinol 2001; 54:617-626.
4. Utz A, Swearingen B, Biller B. Pituitary surgery and postoperative management in Cushing's disease. Endocrinol Metab Clin North Am 2005; 34:459-478; xi.
5. Atkinson A, Kennedy A, Wiggam M, et al. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol 2005; 63:549-559.
6. Ram Z, Nieman L, Cutler GB Jr, et al. Early repeat surgery for persistent Cushing's disease. J Neurosurg 1994; 80:37-45.
7. Friedman R, Oldfield E, Nieman L, et al. Repeat transsphenoidal surgery for Cushing's disease. J Neurosurg 1989; 71:520-527.
8. Benveniste R, King W, Walsh J, et al. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg 2005; 102:1004-1012.
9. Locatelli M, Vance M, Laws E. Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 2005; 90:5478-5482.
10. Katznelson L, Bogan J, Trob J, et al. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab 1998; 83:1619-1623.
11. Cannavo S, Almoto B, Dall'Asta C, et al. Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas. Eur J Endocrinol 2003; 149:195-200.
12. De Tommasi C, Vance M, Okonkwo D, et al. Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing's disease or Nelson's syndrome. J Neurosurg 2005; 103:825-830.
13. Vella A, Thompson G, Grant C, et al. Laparoscopic adrenalectomy for adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 2001; 86:1596-1599.
14. Invitti C, Pecori Giraldi F, De Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999; 84:440-448.
15. Sonino N, Zielezny M, Fava G, et al. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 1996; 81:2647-2652.
16. Jenkins P, Trainer P, Plowman P, et al. The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1995; 80: 165-171.
17. Ahmed S, Shalet S, Beardwell C, Sutton M. Treatment of Cushing's disease with low dose radiation therapy. BMJ 1984; 289:643-646.
18. Littley M, Shalet S, Beardwell C, et al. Long-term follow-up of low-dose external pituitary irradiation for Cushing's disease. Clin Endocrinol 1990; 33:445-455.
19. Estour B, Duthel R, Mounier Ch. Clinical recurrence of Cushing syndrome without evidence of tumor recurrence: radical hypophysectomy? Neurochirurgie 2002; 48:281-284.
20. Hoybye C, Grenback E, Thoren M, et al. Transsphenoidal surgery in Cushing disease: 10 years of experience in 34 consecutive cases. J Neurosurg 2004; 100:634-638.
21. Sheehan J, Niranjan A, Sheehan J, et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 2005; 102:678-691.
22. Mahmoud-Ahmed A, Suh J. Radiation therapy for Cushing's disease: a review. Pituitary 2002; 5:175-180.
23. Martinez R, Bravo G, Burzaco J, Rey G. Pituitary tumors and gamma knife surgery. Clinical experience with more than two years of follow-up. Stereotact Funct Neurosurg 1998; 70 (Suppl 1):110-118.
24. Pollock B, Young WF Jr. Stereotactic radiosurgery for patients with ACTH-producing pituitary adenomas after prior adrenalectomy. Int J Radiat Oncol Biol Phys 2002; 54:839-841.
25. Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 1997; 336:172-177.
26. Sheehan J, Vance M, Sheehan J, et al. Radiosurgery for Cushing's disease after failed transsphenoidal surgery. J Neurosurg 2000; 93:738-742.
27. Ganz J. Gamma knife radiosurgery and its possible relationship to malignancy: a review. J Neurosurg 2002; 97:644-652.
28. Miller J, Crapo L. The medical treatment of Cushing's syndrome. Endocr Rev 1993; 14:443-458.
29. Trainer P, Eastment C, Grossman A, et al. The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing's syndrome. Clin Endocrinol 1993; 39:441-443.
30. Boscaro M, Sonino N, Rampazzo A, et al. ACTH response to corticotropin releasing hormone in Cushing's disease before and after ketoconazole: in vivo and in vitro studies. Horm Metab Res Suppl 1987; 16:60-62.
31. Chou S, Lin J. Long-term effects of ketoconazole in the treatment of residual or recurrent Cushing's disease. Endocr J 2000; 47:401-406.
32. Loli P, Berselli M, Tagliaferri M. Use of ketoconazole in the treatment of Cushing's syndrome. J Clin Endocrinol Metab 1986; 63:1365-1371.
33. McCance D, Hadden D, Kennedy L, et al. Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. Clin Endocrinol 1987; 27:593-599.
34. Sonino N, Boscaro M, Merola G, Mantero F. Prolonged treatment of Cushing's disease by ketoconazole. J Clin Endocrinol Metab 1985; 61:718-722.
35. Colao A, Di Sarno A, Marzullo P, et al. New medical approaches in pituitary adenomas. Horm Res 2000; 53 (Suppl 3):76-87.
36. Vignati F, Loli P. Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. J Clin Endocrinol Metab 1996; 81:2885-2890.
37. Engelhardt D, Weber M. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 1994; 49:261-267.
38. Stalla G, Brockmeier S, Renner U, et al. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol 1994; 130:125-131.
39. Rocheville M, Lange D, Kumar U, et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000; 288:154-157.
40. Mercado-Asis L, Yasuda K, Murayama M, et al. Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease. Endocrinol Jpn 1992; 39:385-395.
41. Casulari L, Naves L, Mello P, et al. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 2004; 62:300-305.
42. Whitehead H, Beacom R, Sheridan B, Atkinson A. The effect of cyproheptadine and/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy. Clin Endocrinol 1990; 32:193-201.
43. Tanakol R, Alagol F, Azizlerli H, et al. Cyproheptadine treatment in Cushing's disease. J Endocrinol Invest 1996; 19:242-247.
44. Suda T, Tozawa F, Mouri T, et al. Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease. J Clin Endocrinol Metab 1983; 56:1094-1099.
45. Colao A, Pivonello R, Tripodi F, et al. Failure of long-term therapy with sodium valproate in Cushing's disease. J Endocrinol Invest 1997; 20:387-392.
46. Chu J, Matthias D, Belanoff J, et al. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 2001; 86:3568-3573.
47. Hofland L, Van der Hoek J, Feelders R, et al. The multiligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005; 152:645-654.
48. Heaney A. Novel medical approaches for the treatment of Cushing's disease. J Endocrinol Invest 2004; 27:591-595.
49. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor-gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998; 95:8806-8811.
50. Cannavo S, Ambrosi B, Chiodini I, et al. Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in Cushing's disease. J Endocrinol Invest 2004; 27:RC8-RC11.
51. Ambrosi B, Dall'Asta C, Cannavo S, et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004; 151:173-178.
52. Paez-Pereda M, Kovalovsky D, Hopfner U, et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 2001; 108:1123-1131.
53. Fernando M, Heaney A. α1-Adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol Endocrinol 2005; 19:3085-3096.